News ArticleSai Life Sciences Appoints Three Senior Managers, Reports Q2 FY27 Financials, and Allots 108,005 Shares Under ESOP
Appointments include Senior VP Human Resources, VP Quality & Regulatory Affairs, Senior VP Corporate Communications; Issued share capital rises following ESOP allotment
Sai Life Sciences Limited announced unaudited standalone and consolidated financial results for Q2 and H1 ending 30th September 2026, appointed three senior management personnel effective 5th November 2026, and completed share allotment of 108,005 equity shares under ESOP plans, increasing paid-up capital to ₹21,25,80,721.
Sai Life Sciences Limited
Financial Results
Sai Life Sciences Limited approved its unaudited standalone and consolidated financial results for the second quarter and half year ended 30th September 2026, appointed three senior management officers on 5th November 2026, and allotted 108,005 equity shares under employee stock option plans, increasing its paid-up capital.
The Board appointment includes Mr. Sidhartha Das as Senior Vice President and Head of Human Resources, Mr. Vijay Kumar Suthari as Vice President and Head of Quality & Regulatory Affairs, and Mr. Sriram Gopalakrishnan as Senior Vice President of Corporate Communications, all effective from 5th November 2026.
Allotment of 27,005 shares under ESOP 2008 and 81,000 shares under MESOP 2018 increased the issued, subscribed, and paid-up equity share capital from ₹21,24,72,716 to ₹21,25,80,721.
Detailed profiles note Mr. Das's 25 years in HR across FMCG and pharmaceuticals, Mr. Suthari's 24 years in pharmaceutical quality and compliance, and Mr. Gopalakrishnan’s 25 years in marketing and communications, bolstering Sai Life Sciences’ senior team.
Highlights
- Unaudited Q2 and H1 FY27 standalone and consolidated financial results approved for period ending 30th September 2026.
- Appointments effective 5th November 2026: Sidhartha Das (SVP HR), Vijay Kumar Suthari (VP Quality & Regulatory Affairs), Sriram Gopalakrishnan (SVP Corporate Communications).
- Share capital increased to ₹21,25,80,721 after allotting 108,005 equity shares under two ESOP plans.
- Board meeting held from 9:20 PM to 9:42 PM IST on 5th November 2026.
Key Data Snapshot
What happened
- Sai Life Sciences approved unaudited standalone and consolidated financial results for Q2 and H1 FY27 ending 30th September 2026.
- The company appointed three senior management personnel effective 5th November 2026.
- The Board approved allotment of 108,005 equity shares under employee stock option plans increasing the paid-up capital.
- The share capital increased from ₹21,24,72,716 to ₹21,25,80,721 following ESOP allotment.
Key details
- Mr. Sidhartha Das appointed as Senior Vice President and Head of Human Resources with over 25 years experience across FMCG, pharmaceuticals, life sciences, and infrastructure sectors.
- Mr. Vijay Kumar Suthari appointed as Vice President and Head of Quality & Regulatory Affairs, having 24 years of pharmaceutical quality assurance and regulatory experience.
- Mr. Sriram Gopalakrishnan appointed as Senior Vice President of Corporate Communications, bringing more than 25 years in brand strategy and corporate communications.
- Appointments classified as Senior Management Personnel according to SEBI Listing Regulations.
- Board meeting commenced at 9:20 PM IST and ended at 9:42 PM IST on 5th November 2026.
Regulatory and governance context
- The announcement complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulations 30 and 33.
- Share allotments adhere to SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
- Corporate governance disclosures include detailed appointment profiles as per SEBI circular dated 30th January 2026.
Highlights
- Unaudited Q2 and H1 FY27 standalone and consolidated financial results approved for period ending 30th September 2026.
- Appointments effective 5th November 2026: Sidhartha Das (SVP HR), Vijay Kumar Suthari (VP Quality & Regulatory Affairs), Sriram Gopalakrishnan (SVP Corporate Communications).
- Share capital increased to ₹21,25,80,721 after allotting 108,005 equity shares under two ESOP plans.
- Board meeting held from 9:20 PM to 9:42 PM IST on 5th November 2026.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026
- SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Sansera Engineering Posts Rs 1,092.53 Million Profit in Q2 2026 After US$2 Million Lawsuit Settlement
Sansera Engineering Limited announced unaudited standalone results for Q2 and half year ended September 30, 2026, registering a net profit of Rs 1,092.53 million for the quarter and Rs 1,959.30 million for six months. The company settled a United States civil lawsuit by paying US$2 million during this period, recognized as an exceptional expense.
Read Full Story
Godfrey Phillips India Announces Q2 FY2027 Financial Results and Rs. 10 Per Share Interim Dividend
Godfrey Phillips India Limited approved its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company declared an interim dividend of 500% or Rs. 10 per equity share of Rs. 2 each for the fiscal year ending March 31, 2027.
Read Full Story
Rubicon Research Limited Reports ₹1,430.69 Million Net Profit for Half Year Ended September 30, 2026
Rubicon Research Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, reporting a net profit after tax of ₹1,430.69 million for the six-month period.
Read Full Story
